The Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT) is a randomized, parallel, placebo-controlled, multicenter trial designed to test the efficacy of a non-selective nonsteriodal anti-inflammatory drug and a selective COX-2 inhibitor for the prevention of Alzheimer's disease and attenuation of age related cognitive decline.  The treatment regimens, are: naproxen sodium (220 mg b.i.d.), celecoxib (200 mg b.i.d.) and matching placebos.  The trial is designed to enroll 2,625 dementia-free participants who are age 70 or older and had or have a first degree relative with Alzheimer-like dementia.  Participants will be assessed periodically for any decline in memory or cognitive function and followed for approximately 7 years.

Home | Centers | Contacts | Documents | Links | Presentations | Publications